US
If visiting the DiaSorin Site from a region that doesn't coincide with your location, some products may not be available. This is due to regulatory requirements and restrictions.
21/12/21 - 11:07
2022 Annual Calendar of Corporate Events (296.13 KB)
Other
16/12/21 - 22:47
DiaSorin 2022-2025 Strategic Plan (552.15 KB)
Financial Data
30/11/21 - 19:10
DiaSorin confirms effectiveness of its Molecular Diagnostic tests in light of new Omicron SARS-CoV-2 Variant (307.83 KB)
Products
Molecular
29/11/21 - 7:06
DiaSorin receives FDA approval for its LIAISON® QuantiFERON®-TB Gold Plus assay for use on the LIAISON® XS Analyzer (437.79 KB)
Products
Immunodiagnostic
23/11/21 - 7:10
DiaSorin launches LIAISON® MeMed BV®, the first high throughput blood test to differentiate between bacterial and viral infections, in countries accepting the CE Mark (412.77 KB)
Products
Immunodiagnostic
11/11/21 - 16:56
DiaSorin business momentum and the Luminex acquisition drive Revenues and Profitability up in the first 9 months of 2021 (862.48 KB)
Financial Data
05/11/21 - 11:22
Weekly report treasury shares buy-back (2.15 MB)
Other
02/11/21 - 20:00
Conclusion treasury shares buy-back plan (294.67 KB)
Other
02/11/21 - 19:57
Weekly report treasury shares buy-back (3.5 MB)
Other
27/10/21 - 16:35
Issuance of the "Physical Settlement Notice" (517.5 KB)
Other
07/10/21 - 11:45
Publication of the summary report of the votes (290.08 KB)
Other
04/10/21 - 12:27
The Extraordinary Shareholders' Meeting of DiaSorin authorizes the convertibility of the equity-linked bond and the share capital increase (297.73 KB)
Other
18/09/21 - 8:16
DiaSorin CE Marks its new Simplexa™ COVID-19 & Flu A/B Direct Assay for Detection and Differentiation of SARS-CoV-2 and Influenza in One Test (407.21 KB)
Products
Molecular
30/07/21 - 18:43
Start up of the treasury shares buy-back plan (773.96 KB)
Other
30/07/21 - 12:57
DiaSorin: Revenues and Profitability continue upward momentum in the First Half of 2021, with Guidance raised following the acquisition of Luminex (774.36 KB)
Financial Data
22/07/21 - 18:28
Publication of Information Document under the provisions of the art. 71 of the CONSOB Regulation n. 11971/1999 (303.95 KB)
Other
14/07/21 - 15:05
DiaSorin announces completion of the Acquisition of Luminex Corporation (566.52 KB)
Acquisition / Partnership
09/07/21 - 7:34
DiaSorin obtains all approvals necessary to complete the acquisition of Luminex (560.68 KB)
Acquisition / Partnership
21/06/21 - 18:49
The Shareholders’ meeting of Luminex Corporation approved the merger of Luminex with a U.S. wholly-owned subsidiary of DiaSorin (395.62 KB)
Acquisition / Partnership
15/06/21 - 6:56
DiaSorin launches the first fully automated CLIA high-throughput solution for diagnosing Hepatitis E (307.58 KB)
Products
Immunodiagnostic
07/06/21 - 15:16
Communication on total amount of voting rights (563.42 KB)
Other
03/06/21 - 7:47
DiaSorin signs agreements with Unifarma and Alliance Healthcare for the distribution in Italian pharmacies of the LIAISON® IQ (523.42 KB)
Acquisition / Partnership
25/05/21 - 7:03
DiaSorin: launch of the LIAISON® Quick Detect COVID Ag assay, an antigen test to detect COVID-19 infection (402.64 KB)
Products
Immunodiagnostic
21/05/21 - 7:02
DiaSorin Releases an Assay for Rapid Identification of Mutations Associated with Circulating Variants of SARS-CoV-2 (393.69 KB)
Products
Molecular
20/05/21 - 8:27
DiaSorin’s LIAISON® SARS-CoV-2 TrimericS IgG test receives FDA Emergency Use Authorization for the U.S. market (506.2 KB)
Products
Immunodiagnostic
14/05/21 - 16:10
DiaSorin: significant growth in Revenues and Profitability in the first quarter 2021 (756.07 KB)
Financial Data
28/04/21 - 17:46
DiaSorin successfully prices its offer of € 500 million Senior Unsecured Equity-Linked Bonds due 2028 (529.64 KB)
Financial Data
28/04/21 - 7:54
DiaSorin announces its intention to offer € 500 million senior unsecured equity-linked bonds due 2028 (563.02 KB)
Financial Data
22/04/21 - 15:58
Shareholders' meeting April 22, 2021 (422.91 KB)
Other
21/04/21 - 7:02
DiaSorin, in partnership with QIAGEN, launches the new LIAISON® LymeDetect® Assay based on QuantiFERON technology (621.42 KB)
Products
Immunodiagnostic
20/04/21 - 18:58
DiaSorin launches the LIAISON® IQ with a first test that detects IgG antibodies against SARS-COV-2 in markets accepting the CE Mark (403.5 KB)
Products
Immunodiagnostic
14/04/21 - 10:05
Communication voting rights amount (544.6 KB)
Other
12/04/21 - 11:08
Weekly report treasury shares buy-back (914.42 KB)
Other
11/04/21 - 19:47
DiaSorin to acquire Luminex Corporation for USD 37.00 per share or approximately USD 1.8 billion (569.09 KB)
Acquisition / Partnership
06/04/21 - 8:53
Start up buy-back plan (774.02 KB)
Other
06/04/21 - 7:06
DiaSorin announces its strategic collaboration with Lumos Diagnostics (438.14 KB)
Acquisition / Partnership
30/03/21 - 7:01
DiaSorin received BARDA funding to develop and achieve FDA regulatory authorization, for its LIAISON® SARS-CoV-2 Ag test (661.47 KB)
Products
Immunodiagnostic
29/03/21 - 7:02
DiaSorin has obtained FDA Emergency Use Authorization for its LIAISON® SARS-CoV-2 Ag for COVID-19 testing in the U.S. (494.1 KB)
Products
Immunodiagnostic
11/03/21 - 16:37
Dividend coupon date correction (414.99 KB)
Financial Data
11/03/21 - 15:31
Revenues, Profitability and Cash Flow Generation hit record highs in 2020 (748.06 KB)
Financial Data
23/02/21 - 6:11
DiaSorin obtained FDA approval for two additional serology tests for Lyme Disease in the U.S. market (413.92 KB)
Products
Immunodiagnostic
27/01/21 - 18:50
2021 Annual Calendar of Corporate Events (209.87 KB)
Other
11/01/21 - 18:43
DiaSorin launches with CE mark the LIAISON® SARS-CoV-2 TrimericS IgG test (418.29 KB)
Products
Immunodiagnostic